Her remission means the world to her.
PROTECT IT.
In the post auto-HSCT consolidation treatment of patients with classical
Hodgkin lymphoma (HL) at high risk of relapse or progression, ADCETRIS®
(brentuximab vedotin) significantly increased PFS compared to placebo1
18.8
ADCETRIS: 42.9 months (95% CI: 30.4, 42.9†)
Placebo: 24.1 months (95% CI: 11.5, NE)
HR=0.57 (95% CI: 0.40, 0.81) P=0.001
month median PFS benefit1
NE=Not estimable. †Estimates are unreliable.
STUDY DESIGN: ADCETRIS was evaluated as post auto-HSCT consolidation treatment in a multicenter, randomized,
double-blind, placebo-controlled trial of 329 patients aged ≥18 years with classical Hodgkin lymphoma (histologically
confirmed) at high risk of relapse or disease progression within 30-45 days post auto-HSCT. Patients were randomized
to receive ADCETRIS 1.8 mg/kg (n=165) or placebo (n=164) q3w for up to 16 cycles. High risk of relapse/progression
was defined by ≥1 of the following risk factors: refractory disease, relapse <12 months after frontline therapy, relapse
≥12 months with extranodal disease. Primary